A Amraee1, M R Evazi2, M Shakeri3, N Roozbeh4, M Ghazanfarpour5, M Ghorbani6, J Ansari7, L Darvish8,9. 1. Department of Medical Physics, Faculty of Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. 2. Hematologist and Medical Oncologist, Hormozgan University of Medical Science, Bandar Abbas, Iran. 3. Department of Radiology and Radiotherapy, Allied Medical Sciences School, Tehran University of Medical Sciences, Tehran, Iran. 4. Mother and Child Welfare Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. 5. Department of Midwifery, Razi School of Nursing and Midwifery, Kerman University of Medical Sciences, Kerman, Iran. 6. Biomedical Engineering and Medical Physics Department, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 7. Department of Radiotherapy & Oncology, Arak University of Medical Sciences, Arak, Iran. 8. Mother and Child Welfare Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. Leilidarvish@gmail.com. 9. Department of Radiology, Faculty of Paramedicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. Leilidarvish@gmail.com.
Abstract
AIMS: The primary standard treatment for classic Hodgkin's lymphoma (cHL) is chemotherapy and radiation therapy. However, some patients get relapsed, or their diseases become resistant. PD1 blocking antibodies have been used to increase the response of treatment in solid tumors, and led to potentially stable responses that are acceptable. Our purpose in this study is to investigate the effect of nivolumab as a PD1 blocking antibody on the survival rate of patients with Hodgkin's cancer. METHODS: Databases were found in International Medical Sciences, Web of Science, Medline, Scopus, Index Copernicus, PubMed, DOAJ, Google Scholar, EBSCO-CINAHL, and Persian databases containing SID and Magiran using keywords such as: "checkpoint inhibitor", "nivolumab", "Hodgkin lymphoma", and "PD1 Blockade". The risk of bias was determined by two external observers using the Cochrane checklists. After the search, the data provided in 51 documents was independently evaluated. Duplicate papers were excluded. Assessing the full texts of the remaining papers, 7 papers were approved. RESULTS: Pooled data of these seven studies revealed that the overall objective response rate was 68% (CI 64.1% to 72.1%; heterogeneity; I2 = 40.19%; p = 0.123) with partial remission (52%; CI 46.5% to 57.6%; heterogeneity; I2 = 28.36%; p = 0.212). In the pooled analysis, complete remission was 16.8 (CI 11.1% to 26.4%). Pooled data of six studies showed that stable disease was averaged to 19% (CI 16% to 23%; heterogeneity; I2 = 30%; p = 0.209; fixed-effect model). CONCLUSIONS: The results of the study indicate that nivolumab as a PD1 pathway inhibitor can be effective in treating relapsed and refractory cHL patients compared to other therapies, and lead to more effective treatment over the long term. Furthermore, the adverse effects of nivolumab are controllable and have a good safety profile.
AIMS: The primary standard treatment for classic Hodgkin's lymphoma (cHL) is chemotherapy and radiation therapy. However, some patients get relapsed, or their diseases become resistant. PD1 blocking antibodies have been used to increase the response of treatment in solid tumors, and led to potentially stable responses that are acceptable. Our purpose in this study is to investigate the effect of nivolumab as a PD1 blocking antibody on the survival rate of patients with Hodgkin's cancer. METHODS: Databases were found in International Medical Sciences, Web of Science, Medline, Scopus, Index Copernicus, PubMed, DOAJ, Google Scholar, EBSCO-CINAHL, and Persian databases containing SID and Magiran using keywords such as: "checkpoint inhibitor", "nivolumab", "Hodgkin lymphoma", and "PD1 Blockade". The risk of bias was determined by two external observers using the Cochrane checklists. After the search, the data provided in 51 documents was independently evaluated. Duplicate papers were excluded. Assessing the full texts of the remaining papers, 7 papers were approved. RESULTS: Pooled data of these seven studies revealed that the overall objective response rate was 68% (CI 64.1% to 72.1%; heterogeneity; I2 = 40.19%; p = 0.123) with partial remission (52%; CI 46.5% to 57.6%; heterogeneity; I2 = 28.36%; p = 0.212). In the pooled analysis, complete remission was 16.8 (CI 11.1% to 26.4%). Pooled data of six studies showed that stable disease was averaged to 19% (CI 16% to 23%; heterogeneity; I2 = 30%; p = 0.209; fixed-effect model). CONCLUSIONS: The results of the study indicate that nivolumab as a PD1 pathway inhibitor can be effective in treating relapsed and refractory cHL patients compared to other therapies, and lead to more effective treatment over the long term. Furthermore, the adverse effects of nivolumab are controllable and have a good safety profile.
Authors: Michael R Green; Scott Rodig; Przemyslaw Juszczynski; Jing Ouyang; Papiya Sinha; Evan O'Donnell; Donna Neuberg; Margaret A Shipp Journal: Clin Cancer Res Date: 2012-01-23 Impact factor: 12.531
Authors: Philippe Armand; Arnon Nagler; Edie A Weller; Steven M Devine; David E Avigan; Yi-Bin Chen; Mark S Kaminski; H Kent Holland; Jane N Winter; James R Mason; Joseph W Fay; David A Rizzieri; Chitra M Hosing; Edward D Ball; Joseph P Uberti; Hillard M Lazarus; Markus Y Mapara; Stephanie A Gregory; John M Timmerman; David Andorsky; Reuven Or; Edmund K Waller; Rinat Rotem-Yehudar; Leo I Gordon Journal: J Clin Oncol Date: 2013-10-14 Impact factor: 44.544
Authors: Janis M Taube; Alison Klein; Julie R Brahmer; Haiying Xu; Xiaoyu Pan; Jung H Kim; Lieping Chen; Drew M Pardoll; Suzanne L Topalian; Robert A Anders Journal: Clin Cancer Res Date: 2014-04-08 Impact factor: 12.531
Authors: Ryan A Wilcox; Andrew L Feldman; David A Wada; Zhi-Zhang Yang; Nneka I Comfere; Haidong Dong; Eugene D Kwon; Anne J Novak; Svetomir N Markovic; Mark R Pittelkow; Thomas E Witzig; Stephen M Ansell Journal: Blood Date: 2009-07-13 Impact factor: 22.113